Observational study of changes in q-space Myelin Map (qMM) imaging in MS patients treated with dimethyl fumarate (DMF)

Observational study of changes in q-space Myelin Map (qMM) imaging in MS patients treated with dimethyl fumarate (DMF) - Observational study of changes in q-space Myelin Map (qMM) imaging in MS patients treated with dimethyl fumarate (DMF)

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035784

Enrollment

Registered

2019-02-07

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient aged from 20 to 60 at the time of consent. Must have a diagnosis of RRMS as defined by 2010 revised McDonald criteria. Must have visible evidence of at least one lesion with qMM worsening signal at baseline. Consented to allow their clinical data entered in the clinical database to be used for research purposes

Exclusion criteria

Exclusion criteria: Concomitant diagnosis of non-MS diseases including cerebral infarction or others that in the opinion of the Investigator would jeopardize the qMM analysis of MS lesions. Diagnosis or history of neuromyelitis optica (NMO), e.g., a long spinal lesion extending over 3 or more vertebral bodies was detected, or the subject has a history of positive tests for anti-aquaporin 4 (anti-AQP4) antibodies. Not consented or refused to allow their clinical data to be used research purpose.

Design outcomes

Primary

Measure	Time frame
Changes in qMM	—

Secondary

Measure	Time frame
Changes in MTR	—

Countries

Japan

Contacts

Public ContactJin Nakahara

Keio University School of Medicine Department of Neurology

nakahara@a6.keio.jp03-3353-1211

Outcome results